Inebilizumab for Treatment of IgG4-Related Disease

This phase 3, multicenter, randomized controlled trial evaluated the efficacy of inebilizumab a CD19-targeting monoclonal antibody in reducing disease flares in patients with IgG4-related disease. Among 135 participants, those treated with inebilizumab had significantly fewer disease flares compared to placebo, and more achieved complete remission without the need for glucocorticoids. Adverse events were similar between groups, although some serious events occurred more frequently in the inebilizumab group. The study highlights inebilizumab as a promising option for managing this chronic immune-mediated condition.

This phase 3, multicenter, randomized controlled trial evaluated the efficacy of inebilizumab a CD19-targeting monoclonal antibody in reducing disease flares in patients with IgG4-related disease. Among 135 participants, those treated with inebilizumab had significantly fewer disease flares compared to placebo, and more achieved complete remission without the need for glucocorticoids. Adverse events were similar between groups, although some serious events occurred more frequently in the inebilizumab group. The study highlights inebilizumab as a promising option for managing this chronic immune-mediated condition.